Marker Therapeutics Inc (MRKR)

[microcapbiotech]

This has to be Marker. All the authors are from Baylor.

Spyridoula Vasileiou, PhD1; Premal D. Lulla, MD1; Ifigeneia Tzannou, MD1; Ayumi Watanabe, BSc1; Manik Kuvalekar, MSc1; Wendy L. Callejas, BSc1; Mrinalini Bilgi, BSc1; Tao Wang, PhD1; Mengfen J. Wu, BSc1; Rammurti Kamble, MD1; Carlos A. Ramos, MD1; Rayne H. Rouce, MD1; Zihua Zeng, MD1; Adrian P. Gee, PhD1; Bambi J. Grilley, RPh1; Juan F. Vera, MD1; Catherine M. Bollard, MD1; Malcolm K. Brenner, MD, PhD1; Helen E. Heslop, MD1; Cliona M. Rooney, PhD1; Ann M. Leen, PhD1; and George Carrum, MD1
1Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, TX

I see Juan Vera, Helen Heslop, Ann Leen.
The 5 TAA targets are what Marker is using.